Clinical characteristics of non-Latino White, non-Latino Black and Latino prostate cancer patients in California who did not received treatment and were not under active surveillance/watchful waiting (1995-2021).
ARTICLE ABSTRACT
We investigated clinical characteristics and prostate cancer survival patterns among Latino patients considering nativity compared with non-Latino Black (NLB) and non-Latino White (NLW) patients.
We used data from the California Cancer Registry (1995–2021), which included 347,540 NLW, 50,032 NLB, and 75,238 Latino patients with prostate cancer. Frequencies of sociodemographic and clinical variables were assessed using χ2 tests. Multivariable regression models were fitted to evaluate determinants of treatment reception, Gleason upgrade, and survival differences. Exploratory analyses were conducted grouping Latino cases into US born and non–US born by country of origin.
Compared with NLW, NLB cases had the greatest proportion of younger patients, whereas non–US-born Latino patients had the greatest proportion of low socioeconomic status and uninsured patients. Non–US-born Latinos showed a greater proportion of diagnoses completed with <6 core biopsies, Gleason >8, stage IV tumors, and metastasis. Multivariable analyses showed that compared with NLW, Latino patients were as likely to receive treatment, whereas NLB cases were less likely (OR = 0.81; 95% confidence interval, 0.67–0.98; P = 0.029). Compared with NLW, non–US-born Latino cases were less likely to die of prostate cancer (HR = 0.78; 95% confidence interval, 0.64–0.94; P = 0.011), with no difference reported for NLB cases.
Considering sociodemographic and clinical characteristics, non–US-born Latino patients with prostate cancer had better survival than NLW. This highlights the need to identify key determinants of these survival differences and the importance of sociodemographic and clinical determinants in survival disparities.
Our study emphasizes the importance of considering nativity among Latino patients to understand prostate cancer disparities and outcomes in this population.
